The 36-month beta value for WVE is also noteworthy at -0.97. There are mixed opinions on the stock, with 9 analysts rating it as a “buy,” 3 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for WVE is 124.26M, and at present, short sellers hold a 11.98% of that float. The average trading volume of WVE on July 10, 2025 was 1.33M shares.
WVE) stock’s latest price update
Wave Life Sciences Ltd (NASDAQ: WVE) has experienced a rise in its stock price by 10.79% compared to its previous closing price of $6.95. However, the company has seen a gain of 18.19% in its stock price over the last five trading days. seekingalpha.com reported 2025-07-07 that Wave Life Sciences Ltd. is an innovative biotech with soli data for its AATD, Huntington’s, and DMD programs. Its share price is nevertheless down 44% year-to-date, potentially creating a buying opportunity for a risk-on investor. Wave is partnered with GSK over its AATD program which recently demonstrated proof-of-concept and opens up the possibility of triple-digit million milestone payments.
WVE’s Market Performance
Wave Life Sciences Ltd (WVE) has seen a 18.19% rise in stock performance for the week, with a 6.65% gain in the past month and a 32.76% surge in the past quarter. The volatility ratio for the week is 6.08%, and the volatility levels for the past 30 days are at 5.90% for WVE.. The simple moving average for the past 20 days is 11.40% for WVE’s stock, with a -23.78% simple moving average for the past 200 days.
Analysts’ Opinion of WVE
Many brokerage firms have already submitted their reports for WVE stocks, with Raymond James repeating the rating for WVE by listing it as a “Outperform.” The predicted price for WVE in the upcoming period, according to Raymond James is $14 based on the research report published on June 11, 2025 of the current year 2025.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see WVE reach a price target of $10. The rating they have provided for WVE stocks is “Overweight” according to the report published on April 29th, 2025.
Wedbush gave a rating of “Outperform” to WVE, setting the target price at $18 in the report published on April 08th of the current year.
WVE Trading at 14.02% from the 50-Day Moving Average
After a stumble in the market that brought WVE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.99% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at WVE starting from Verdine Gregory L., who sale 30,000 shares at the price of $6.95 back on Jun 13 ’25. After this action, Verdine Gregory L. now owns 282,517 shares of Wave Life Sciences Ltd, valued at $208,500 using the latest closing price.
Stock Fundamentals for WVE
Current profitability levels for the company are sitting at:
- -1.2 for the present operating margin
- 1.0 for the gross margin
The net margin for Wave Life Sciences Ltd stands at -1.07. The total capital return value is set at -0.63. Equity return is now at value -105.50, with -42.90 for asset returns.
Based on Wave Life Sciences Ltd (WVE), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -7.65.
Currently, EBITDA for the company is -101.74 million with net debt to EBITDA at 1.87. When we switch over and look at the enterprise to sales, we see a ratio of 9.32. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.95.
Conclusion
In summary, Wave Life Sciences Ltd (WVE) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
